The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Sign Up to like & getrecommendations! Published in 2017 at "European journal of cancer"
DOI: 10.1016/j.ejca.2017.01.011
Abstract: Indoleamine 2,3-dioxygenase (IDO, also referred to as IDO1) has been demonstrated to be a normal endogenous mechanism of acquired peripheral immune tolerance in vivo. In the field of oncology, IDO expression and/or activity has been observed… read more here.
Keywords: rationale indoleamine; inhibition; dioxygenase inhibition; cancer ... See more keywords
A suppressor of dioxygenase inhibition in a yeast model of SDH deficiency.
Sign Up to like & getrecommendations! Published in 2022 at "Endocrine-related cancer"
DOI: 10.1530/erc-21-0349
Abstract: A fascinating class of familial paraganglioma (PGL) neuroendocrine tumors is driven by loss of the tricarboxylic acid (TCA) cycle enzyme succinate dehydrogenase (SDH) resulting in succinate accumulation as an oncometabolite, and other metabolic derangements. Here… read more here.
Keywords: dioxygenase inhibition; yeast model; yeast; model ... See more keywords